Advancing RNA

For ultra-short shelf-life therapies, waiting 14 days for sterility results just isn’t realistic, but releasing product early comes with real risk. In this conversation, Jose Caraballo Oramas breaks down how teams are rethinking sterility testing, contamination control, and release decisions for ATMPs, including the shift toward rapid microbial methods and more integrated process strategies. A really interesting look at how clinical reality is forcing the industry to evolve. https://lnkd.in/eXChFzEj

AI isn’t just transforming protein modeling, it’s starting to unlock RNA biology in a big way. In this piece, Haopeng Yu and Yiliang Ding break down how foundation models are helping decode RNA sequence, structure, and function. Worth a read if you’re following where AI is headed in molecular biology. https://lnkd.in/ePgBgNHE

Personalized cancer vaccines are pushing immuno-oncology forward, but delivery and manufacturing hurdles still stand in the way. In this webinar, Cytiva explores how optimized ionizable LNPs can improve mRNA vaccine delivery, tolerability, and tumor response, while supporting small-scale clinical manufacturing strategies that help move PCV candidates from concept to clinic with greater confidence. #Cytiva #CancerVaccines #ImmunoOncology

Personalized cancer vaccines are pushing immuno-oncology forward, but delivery and manufacturing hurdles still stand in the way. In this webinar, Cytiva explores how optimized ionizable LNPs can improve mRNA vaccine delivery, tolerability, and tumor response, while supporting small-scale clinical manufacturing strategies that help move PCV candidates from concept to clinic with greater confidence. #Cytiva #CancerVaccines #ImmunoOncology

If you’re working with guide RNA, you already know the bottleneck isn’t discovery, it’s manufacturing and quality. Tomorrow at 11am we'll get into the gaps that still exist with solid phase synthesis and current analytical approaches and where things need to evolve next. Led by Anna Rose Welch with experts from Life Edit Therapeutics and Genentech, it’s a focused discussion on what’s actually limiting gRNA quality today and how to improve it. https://lnkd.in/eJq3Qypd

We talk a lot about LNP innovation… but are we actually solving the right problems? In this new piece, Anna Rose Welch sits down with Axelyf CEO Örn Almarsson to unpack where RNA-LNP delivery really stands today. A few things that stood out: • Better analysis, still unclear in vivo behavior • Targeted delivery just getting started • Potency vs tolerability still a challenge • Science alone doesn’t equal success If you’re working in RNA, drug delivery, or early-stage development, this is worth a read. https://lnkd.in/eVsFNci4

What is actually happening with mRNA in the U.S. right now? Not the headlines. Not the noise. The real picture. In this new mRNA Hot Takes episode, Anna Rose Welch talks with Sophia Lugo and Michelle Lynn Hall about the gap between perception and reality when it comes to the future of mRNA in the U.S. They get into: ✅ how much of the panic is policy-driven vs. market-driven ✅ what investors are really thinking ✅ where misinformation is doing the most damage ✅ why education and visible patient benefit matter so much It is a sharp, honest conversation about science, business, policy, and what the industry does next. https://lnkd.in/egB-FdeP

We’re pleased to welcome Maxwell De Long, Director of Strategy and Operations at Genentech, to our upcoming panel on Advancements in gRNA Manufacturing & Quality. Maxwell brings extensive experience in drug development operations, CDMO strategy, technology transfer, and CMC development across modalities including cell therapies, viral vectors, and RNA-based therapeutics. Don’t miss his perspective on navigating the complexities of manufacturing and operational strategy for emerging therapies. https://lnkd.in/eqSEv5NF

Evaluating new CGT technologies? We’ve made it easier. The Cell & Gene Tech Expo runs April 7–9, with dedicated sessions for Cell Therapy, Gene Therapy, and Commercial Readiness. Short presentations, live Q&A, and practical insights to help you move forward with confidence. Register free: https://lnkd.in/dnbPyrax

What’s in Alnylam’s playbook for scaling siRNA production? This article explores how the company is approaching chemoenzymatic ligation, the lessons learned so far, and what it could mean for the future of RNA manufacturing. https://lnkd.in/dwrYisut